EGFR and cancer: While this is often attributed to deregulation of the respective soluble mediators, such as VEGF or interleukins7,11, activation of oncogenic RAS or EGFR also impacts the particulate (insoluble) secretome of cancer cells including the composition of extracellular vesicles (EVs) and particles (EPs)12.